FENC Stock Overview
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Fennec Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.24 |
| 52 Week High | US$11.92 |
| 52 Week Low | US$6.30 |
| Beta | 0.40 |
| 1 Month Change | -16.00% |
| 3 Month Change | -11.32% |
| 1 Year Change | 13.24% |
| 3 Year Change | 38.32% |
| 5 Year Change | 105.79% |
| Change since IPO | -91.85% |
Recent News & Updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 18
Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates
Nov 09Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children
Sep 20Buying Fennec Pharma Ahead Of September PDUFA For Pedmark
Aug 23Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor
Aug 01Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
Oct 29Fennec Could See Upside If Pedmark Gets Approved
Jul 29Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow
Jun 18Fennec Pharma resubmits PEDMARK application in U.S.
May 28Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans
May 26Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 01Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?
Mar 02Have Insiders Been Selling Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares This Year?
Jan 26Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Are In A Position To Invest In Growth
Dec 22Fennec Pharmaceuticals EPS misses by $0.05
Nov 16Fennec Pharmaceuticals: The Compensation Is What's Missing
Nov 05Shareholder Returns
| FENC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.7% | 1.5% | 1.2% |
| 1Y | 13.2% | 1.1% | 24.7% |
Return vs Industry: FENC exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: FENC underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| FENC volatility | |
|---|---|
| FENC Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FENC has not had significant price volatility in the past 3 months.
Volatility Over Time: FENC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 29 | Rosty Raykov | www.fennecpharma.com |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Fennec Pharmaceuticals Inc. Fundamentals Summary
| FENC fundamental statistics | |
|---|---|
| Market cap | US$250.45m |
| Earnings (TTM) | -US$16.04m |
| Revenue (TTM) | US$21.25m |
11.8x
P/S Ratio-15.6x
P/E RatioIs FENC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FENC income statement (TTM) | |
|---|---|
| Revenue | US$21.25m |
| Cost of Revenue | US$1.26m |
| Gross Profit | US$19.99m |
| Other Expenses | US$36.04m |
| Earnings | -US$16.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 94.08% |
| Net Profit Margin | -75.50% |
| Debt/Equity Ratio | -266.1% |
How did FENC perform over the long term?
See historical performance and comparison